Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06795048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Study acronym: CONSTANCE
StatusActive, Not Recruiting
PhasePhase 4
Started2025-03-14
View on ClinicalTrials.gov ↗
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Amendment record

Amended 17 times since 2025-01-24; most recent filed 2026-07-30. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-07-30
Amendment Study Status v17
2026-07-28
Amendment Study Status, Contacts/Locations v16
2026-04-29
Amendment Study Status v15
2026-01-29
Amendment Study Status, Contacts/Locations v14
2025-10-31
Amendment Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v13
2025-10-03
Amendment Study Status, Contacts/Locations v12
2025-09-03
Amendment Study Status, Contacts/Locations v11
2025-08-06
Amendment Study Status, Contacts/Locations v10
2025-07-09
Amendment Study Status, Contacts/Locations v9
2025-06-20
Amendment Study Status, Contacts/Locations v8
2025-05-22
Amendment Study Status, Contacts/Locations v7
2025-04-24
Amendment Study Status, Contacts/Locations v6
2025-03-28
Amendment Study Status, Contacts/Locations v5
2025-03-18
Amendment Study Status v4
2025-03-14
Amendment Study Status, Contacts/Locations v3
2025-03-10
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2025-02-21
Amendment Study Status v1
2025-01-24
Original filing
Trial Details
NCT Number NCT06795048
Lead Sponsor Hoffmann-La Roche
Conditions Neovascular Age-related Macular Degeneration (nAMD)
Enrollment 274 participants
Start Date 2025-03-14
Primary Completion 2026-10-20 (estimated)
Study Completion 2027-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-31